Headache & Migraine
News from the FDA/CDC
The approval of lasmiditan (Reyvow) is based on a pair of randomized, double-blind, placebo-controlled trials that included more than 3,000...
From the Journals
In an open-label study, patients used noninvasive vagus nerve stimulation to treat acute vestibular migraine attacks.
The subdural hematoma rate increased slightly, but significantly, to 147 per 100,000 deliveries.
People with a history of migraines may be at greater risk of developing Alzheimer’s disease and dementia.
PHILADELPHIA – The monoclonal antibody effectively reduces the number of monthly migraine headache days and...
The guidelines review both pharmacologic and nonpharmacologic options, which have multiplied since the previous guidelines were released in 2004...
PHILADELPHIA – Data from two ubrogepant pivotal trials showed similar migraine pain relief in triptan-ineffective and triptan-effective patients...
PHILADELPHIA – Data from 11 million U.S. pediatric inpatients showed a doubled rate of migraine diagnoses among kids hospitalized for asthma.
PHILADELPHIA – Impairment is detected at 1.5 hours after dosing and is resolved by 8 hours after dosing.
PHILADELPHIA – Among patients with episodic cluster headache, use of acute medications is high, but use of...